Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $23.86.
Several equities analysts have commented on the stock. Citigroup reiterated a “market outperform” rating on shares of Immix Biopharma in a report on Wednesday, September 30th. Needham & Company LLC raised their target price on shares of Immix Biopharma from $21.00 to $30.00 and gave the stock a “buy” rating in a research note on Tuesday, September 29th. HC Wainwright raised their target price on shares of Immix Biopharma from $20.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immix Biopharma in a report on Thursday, October 15th. Finally, Mizuho set a $23.00 price target on shares of Immix Biopharma in a research note on Thursday, October 29th.
Get Our Latest Analysis on Immix Biopharma
Hedge Funds Weigh In On Immix Biopharma
A number of large investors have recently made changes to their positions in IMMX. Blue Owl Capital Holdings LP bought a new position in Immix Biopharma during the 2nd quarter worth $4,511,000. Bank of America Corp DE acquired a new stake in shares of Immix Biopharma during the second quarter worth $4,260,000. Wellington Management Group LLP bought a new stake in shares of Immix Biopharma in the second quarter valued at about $15,191,000. Tocqueville Asset Management L.P. bought a new stake in shares of Immix Biopharma in the second quarter valued at about $913,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Immix Biopharma in the second quarter valued at about $1,514,000. Institutional investors own 11.26% of the company’s stock.
Immix Biopharma Stock Down 2.9%
Shares of IMMX stock traded down $0.23 during trading on Friday, reaching $7.84. 1,027,813 shares of the company’s stock were exchanged, compared to its average volume of 1,218,249. Immix Biopharma has a twelve month low of $3.56 and a twelve month high of $15.10. The firm’s fifty day moving average price is $9.82 and its 200-day moving average price is $9.58. The stock has a market capitalization of $560.87 million, a PE ratio of -9.45 and a beta of 0.29.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.19). As a group, analysts anticipate that Immix Biopharma will post -0.76 EPS for the current fiscal year.
Immix Biopharma Company Profile
Immix Biopharma is a clinical-stage biopharmaceutical company developing cell therapies for serious diseases, with a focus on relapsed or refractory AL amyloidosis, a rare condition in which abnormal proteins build up in organs and tissues. The company’s lead candidate, NXC-201, is an investigational CAR T-cell therapy designed to target BCMA, a protein found on certain plasma cells. It is being studied in clinical trials and has not been approved for commercial use. Immix Biopharma is based in the United States and is led by Chief Executive Officer Ilya Rachman.
Recommended Stories
- Five stocks we like better than Immix Biopharma
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
